Breaking News Instant updates and real-time market news.

ACHN

Achillion

$3.97

0.03 (0.76%)

15:25
08/08/17
08/08
15:25
08/08/17
15:25

Achillion to host conference call

Conference call to discuss results for Q2 and provide an update on the company's factor D inhibitor platform will be held on August 8 at 4:05 pm. Webcast Link

  • 08

    Aug

ACHN Achillion
$3.97

0.03 (0.76%)

05/18/17
LEER
05/18/17
UPGRADE
Target $6
LEER
Outperform
Achillion upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded Achillion Pharmaceuticals (ACHN) and raised his price target for the shares to $6 from $4. The analyst sees limited downside from current share levels even if the complement study fails, assuming the hepatitis C virus partnership with Johnson & Johnson (JNJ) remains intact. Schwartz assigned a "conservative" 33% probability of success to Achillion's complement program due to the lack of precedent for an oral small molecule inhibitor of complement factor D that is selective enough to avoid off target effects. He believes risks to successful ACH-4471 development are fully discounted in Achillion's current stock price.
04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/24/17
BARD
04/24/17
NO CHANGE
Target $5
BARD
Outperform
Achillion price target lowered to $5 from $10 at Baird
Baird analyst Brian Skorney lowered his price target on Achillion (ACHN) to $5 from $10 on its disappointing Hep-C results, which indicated a weakness when it comes to genotype 3 patients. Although he expects partner Johnson & Johnson (JNJ) to push the trial into Phase 3, he think it makes the regimen a more difficult sell with other drugs offering genotype 3 efficacy. Skorney maintained his Outperform rating on Achillion shares.

TODAY'S FREE FLY STORIES

TROV

Trovagene

$0.83

0.0165 (2.04%)

16:55
06/18/18
06/18
16:55
06/18/18
16:55
Hot Stocks
Breaking Hot Stocks news story on Trovagene »

Bigger Capital Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVH

Evolent Health

$23.30

0.05 (0.22%)

16:52
06/18/18
06/18
16:52
06/18/18
16:52
Recommendations
Evolent Health analyst commentary  »

Evolent Health Deaconess…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYTM

Rhythm Pharmaceuticals

$28.81

-3.8 (-11.65%)

16:50
06/18/18
06/18
16:50
06/18/18
16:50
Syndicate
Breaking Syndicate news story on Rhythm Pharmaceuticals »

Rhythm Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CC

Chemours

$48.62

-0.84 (-1.70%)

16:47
06/18/18
06/18
16:47
06/18/18
16:47
Hot Stocks
Chemours announces global price increase of up to 15% for all grades of Vazo »

Chemours announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$15.82

0.05 (0.32%)

16:45
06/18/18
06/18
16:45
06/18/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Acadia »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

TAX

Liberty Tax

$8.40

-0.4 (-4.55%)

16:40
06/18/18
06/18
16:40
06/18/18
16:40
Hot Stocks
Liberty Tax receives noncompliance letter from Nasdaq »

Liberty Tax announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNK

Cinemark

$36.17

0.37 (1.03%)

, AMC

AMC Entertainment

$16.00

0.4 (2.56%)

16:38
06/18/18
06/18
16:38
06/18/18
16:38
Hot Stocks
Cinemark and Cineworld acquire remaining stake in NationalCineMedia for $156.8M »

Cineworld Group and…

CNK

Cinemark

$36.17

0.37 (1.03%)

AMC

AMC Entertainment

$16.00

0.4 (2.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$68.36

0.59 (0.87%)

16:38
06/18/18
06/18
16:38
06/18/18
16:38
Earnings
Deluxe backs FY18 adjusted EPS view $5.60-$5.80, consensus $5.71 »

Cuts FY18 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$68.36

0.59 (0.87%)

16:37
06/18/18
06/18
16:37
06/18/18
16:37
Earnings
Deluxe backs Q2 adjusted EPS view $1.29-$1.35, consensus $1.31 »

Cuts Q2 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLX

Deluxe

$68.36

0.59 (0.87%)

16:36
06/18/18
06/18
16:36
06/18/18
16:36
Hot Stocks
Deluxe enters pact to buy treasury management business »

Deluxe Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBSV

ObsEva

$17.21

2.68 (18.44%)

16:35
06/18/18
06/18
16:35
06/18/18
16:35
Syndicate
ObsEva files to sell 4.75M shares of common stock »

J.P. Morgan Securities,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

TAX

Liberty Tax

$8.40

-0.4 (-4.55%)

16:35
06/18/18
06/18
16:35
06/18/18
16:35
Hot Stocks
Liberty Tax names Michael Piper CFO »

Liberty Tax announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGL

Sol-Gel Technologies

$8.50

(0.00%)

16:35
06/18/18
06/18
16:35
06/18/18
16:35
Hot Stocks
Sol-Gel Technologies initiates phase 3 program for Papulopustular Rosacea »

Sol-Gel Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

OMP

Oasis Midstream Partners

$17.59

0.3 (1.74%)

16:33
06/18/18
06/18
16:33
06/18/18
16:33
Hot Stocks
Oasis Midstream Partners signs multiple 3rd party agreements in Williston Basin »

Oasis Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

CL

Colgate-Palmolive

$63.30

-1.43 (-2.21%)

16:32
06/18/18
06/18
16:32
06/18/18
16:32
Hot Stocks
Colgate-Palmolive announces $5B share repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

R

Ryder

$73.69

0.49 (0.67%)

16:31
06/18/18
06/18
16:31
06/18/18
16:31
Hot Stocks
Ryder acquires Metro Truck & Tractor Leasing, terms not stated »

Ryder System announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$63.30

-1.43 (-2.21%)

16:30
06/18/18
06/18
16:30
06/18/18
16:30
Hot Stocks
Breaking Hot Stocks news story on Colgate-Palmolive »

Colgate-Palmolive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
06/18/18
06/18
16:30
06/18/18
16:30
Options
Preliminary option volume of 17.3M today »

Preliminary option volume…

KKR

KKR

$24.00

0.085 (0.36%)

, ATCEY

Altice

$0.00

(0.00%)

16:28
06/18/18
06/18
16:28
06/18/18
16:28
Periodicals
KKR near deal to acquire stake in Altice's telecom towers unit, Reuters says »

KKR (KKR) is near a deal…

KKR

KKR

$24.00

0.085 (0.36%)

ATCEY

Altice

$0.00

(0.00%)

BX

Blackstone

$33.03

-0.23 (-0.69%)

AZSEY

Allianz

$0.00

(0.00%)

AXAHY

AXA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLLI

Ollie's Bargain Outlet

$75.85

0.75 (1.00%)

16:27
06/18/18
06/18
16:27
06/18/18
16:27
Initiation
Ollie's Bargain Outlet initiated  »

Ollie's Bargain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$32.16

-1.24 (-3.71%)

16:27
06/18/18
06/18
16:27
06/18/18
16:27
Syndicate
PagSeguro Digital files to sell 33M shares of Class A common stock »

11,550,000 Class A common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRBK

Green Brick

$12.15

-0.15 (-1.22%)

16:24
06/18/18
06/18
16:24
06/18/18
16:24
Syndicate
Green Brick files to sell 10.7M shares of common stock »

The company is selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHCI

Comstock Holding

$3.38

-0.05 (-1.46%)

16:23
06/18/18
06/18
16:23
06/18/18
16:23
Hot Stocks
Comstock Holding names Christopher Guthrie new CFO »

Comstock Holding Companie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

$181.37

-1.27 (-0.70%)

16:20
06/18/18
06/18
16:20
06/18/18
16:20
Downgrade
F5 Networks rating change  »

F5 Networks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

JD

JD.com

$43.75

0.12 (0.28%)

, GOOG

Alphabet

$1,173.63

21.68 (1.88%)

16:20
06/18/18
06/18
16:20
06/18/18
16:20
General news
On The Fly: Top stock stories for Monday »

Stocks began the week in…

JD

JD.com

$43.75

0.12 (0.28%)

GOOG

Alphabet

$1,173.63

21.68 (1.88%)

GOOGL

Alphabet Class A

$1,183.98

24.95 (2.15%)

SQ

Square

$66.19

1.635 (2.53%)

RCII

Rent-A-Center

$14.68

2.655 (22.08%)

WPC

W.P. Carey

$65.73

-1.32 (-1.97%)

ARWR

Arrowhead

$13.72

2.65 (23.94%)

CBPO

China Biologic

$99.29

17.39 (21.23%)

CBIO

Catalyst Biosciences

$9.07

-16.26 (-64.19%)

ZIOP

Ziopharm

$3.51

-0.805 (-18.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 18

    Jun

  • 20

    Jun

  • 28

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.